Abstract
BackgroundRecently, we have shown that in an Austrian rituximab-registry RA-patients with a low percentage of CD95+ post-switch B cells will benefit more profoundly from a B cell depleting therapy.ObjectivesThe purpose...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
